US Judge Dismisses WPATH Case Against FTC but Transgender Healthcare Dispute Continues

A US federal judge has dismissed a lawsuit brought by the World Professional Association for Transgender Health against the Federal Trade Commission, but a separate legal battle involving the organisation’s medical guidance is continuing.

The ruling, issued on Thursday 29 October 2026, follows the withdrawal of an investigative demand that WPATH argued was intended to punish it for supporting gender-affirming healthcare.

Chief Judge James Boasberg concluded that the withdrawal meant there was no longer an active dispute requiring a decision from the court. His ruling does not establish that the FTC acted lawfully when it originally pursued the investigation, nor does it resolve the separate allegations being considered in Texas.

Why did WPATH challenge the investigation?

WPATH is an international professional organisation that develops clinical guidance for healthcare professionals working with transgender and gender-diverse patients.

Its Standards of Care cover assessments, treatment options and professional responsibilities, and have become central to legal and political disputes concerning gender-affirming healthcare.

The FTC issued an investigative demand seeking information connected to the organisation’s published guidance and representations about medical treatment.

WPATH challenged the demand, arguing that the regulator was targeting its professional advocacy and attempting to interfere with constitutionally protected speech.

The organisation maintained that allowing the investigation to proceed could discourage medical associations from publishing guidance on controversial healthcare subjects.

The FTC disputed WPATH’s position and maintained that its investigation concerned potentially misleading representations about treatment.

What did the judge originally decide?

In May, Judge Boasberg granted preliminary protection against enforcement of the investigative demand.

He found that WPATH had demonstrated a likelihood of succeeding with its argument that the FTC’s actions amounted to retaliation for protected speech.

That finding was made during preliminary proceedings and did not constitute a final judgment after a full examination of the case.

The FTC subsequently withdrew the disputed demand, removing the immediate action WPATH had asked the court to prevent.

Why has the case now been dismissed?

The latest ruling concerns a legal principle known as mootness, which applies when the circumstances behind a lawsuit have ended and a court can no longer provide meaningful relief.

Because the FTC was no longer attempting to enforce the demand, Judge Boasberg concluded that the Washington proceedings could not continue.

The dismissal does not overturn the earlier preliminary concerns about retaliation, but it also does not produce a final ruling that WPATH’s constitutional rights were violated.

That distinction is important because the organisation remains involved in another legal dispute concerning its medical guidance.

What is happening in the Texas lawsuit?

The FTC has pursued separate proceedings in Texas, alleging that WPATH made misleading claims concerning the safety and effectiveness of certain gender-affirming treatments for minors.

WPATH disputes those allegations and maintains that its clinical guidance reflects professional assessments of the available medical evidence.

The Texas proceedings are separate from the withdrawn investigative demand considered by Judge Boasberg, meaning the Washington dismissal does not bring that case to an end.

The allegations have not been established through a final court judgment.

What does the ruling mean for transgender healthcare?

The dispute raises wider questions about the relationship between government regulators, medical organisations and professional freedom of expression.

WPATH does not directly provide medical treatment, but its published guidance influences discussions among clinicians, healthcare providers and policymakers internationally.

The organisation’s legal challenges also form part of a wider series of US court proceedings concerning access to transgender healthcare and the powers of federal agencies.

SoapLandTV has previously reported on a separate Supreme Court decision concerning healthcare for transgender prisoners, although that case involved different legal questions and should not be confused with the FTC investigation.

The 29 October ruling closes WPATH’s challenge to the withdrawn investigative demand, while the separate Texas lawsuit continues.

Related SoapLandTV coverage: US Supreme Court Rejects Trump’s Restrictions on Transgender Prisoners’ Healthcare